Artivion Acquires Endospan for $175M Plus $200M Contingent After FDA PMA Approval
Artivion closed its $175M acquisition of Endospan, with up to $200M contingent on U.S. NEXUS system performance after FDA PMA approval of the NEXUS Aortic Arch System. It adds the first off-the-shelf endovascular arch solution to Artivion’s three-pronged aortic portfolio, boosting its global leadership as it readies for U.S. launch.
1. Acquisition Details
Artivion has completed its acquisition of Endospan for $175 million upfront, less loan offsets, plus up to $200 million in contingent payments tied to U.S. NEXUS System commercial performance over the next two years.
2. FDA PMA Approval of NEXUS System
The FDA granted PMA approval for the NEXUS Aortic Arch System in April 2026, marking the first off-the-shelf endovascular solution for ascending and aortic arch disease in high-risk patients.
3. Portfolio Integration and Market Reach
Adding NEXUS complements Artivion’s AMDS and ARCEVO LSA offerings, creating the only comprehensive aortic arch portfolio and leveraging Artivion’s exclusive EMEA distribution since 2019 to expand global market penetration.
4. Pipeline and Commercial Launch Plans
Artivion is preparing for a full U.S. launch of NEXUS while advancing next-generation arch technologies, positioning the company for sustained leadership in the aortic arch market.